Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ziyad Jabaji

Colon & Rectal Surgery Thousand Oaks, CA Medical Doctor

NPI 1366760514 CMS profile 857319

77 Rolling Oaks Dr, Ste 203, Thousand Oaks, CA 91361

Open in the dashboard

General payments

$12,778

43 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ziyad Jabaji of Thousand Oaks, CA is reported in the CMS Open Payments database as having received $12,778 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Colon & Rectal Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $455 7
2024 General $209 5
2023 General $7,766 16
2022 General $3,370 5
2020 General $379 3
2019 General $598 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ziyad Jabaji
  • Colon & Rectal Surgery median
  • Middle half of Colon & Rectal Surgery
  • National median

In program year 2025, general payments to Ziyad Jabaji were reported at $455. Among 1,481 Colon & Rectal Surgery profiles paid that year, the median was $317 and the middle half received between $109 and $1,248.

Show as a table
Year Ziyad Jabaji Colon & Rectal Surgery median Middle half National median
2019 $598 $443 $125–$2,179 $163
2020 $379 $167 $53–$931 $114
2021 $0 $207 $72–$1,272 $132
2022 $3,370 $341 $111–$1,587 $149
2023 $7,766 $322 $115–$1,420 $160
2024 $209 $328 $112–$1,354 $164
2025 $455 $317 $109–$1,248 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $11,149 21 payments
  2. Prescient Surgical $274 1 payment
  3. Applied Medical Resources Corporation $191 2 payments
  4. THD America, Inc. $170 1 payment
  5. W. L. Gore & Associates, Inc. $168 6 payments
  6. Olympus Corporation of the Americas $162 4 payments
  7. Medtronic, Inc. $148 2 payments
  8. Boston Scientific Corporation $132 1 payment
  9. Vertex Pharmaceuticals Incorporated $125 1 payment
  10. Ethicon US, LLC $96 1 payment
  11. Other $162 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $9,500 3 payments
  2. Food and Beverage $1,868 29 payments
  3. Travel and Lodging $1,409 11 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $5,649 19 payments
  2. DAVINCI XI $5,500 2 payments
  3. CleanCision $274 1 payment
  4. EVIS EXERA $162 4 payments
  5. Olympus Capital Accessories $162 4 payments
  6. Olympus Surgical Accessories $145 3 payments
  7. Olympus Laparoscopic Accessories $145 3 payments
  8. RESOLUTION CLIP $132 1 payment
  9. JOURNAVX $125 1 payment
  10. INTERSTIM $113 1 payment
  11. Other $607 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

100

Median for Surgical Oncology: 44

Drug cost

$621

Median for Surgical Oncology: $327

Branded share of claims

13%

Median for Surgical Oncology: 14.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 13 $209
Neomycin Sulfate Generic 24 $157
Ciprofloxacin Hcl Generic 22 $95
Metronidazole Generic 27 $92
Gabapentin Generic 14 $69

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 682 Part D prescribers listed as Surgical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$38,289

Medicare's payments for the services billed

Medicare patients

68

Average age 71

Services billed

184

29 women, 39 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 47%
Diabetes 44%
Arthritis 41%
Chronic kidney disease 38%
Depression 32%
Heart failure 25%
Ischemic heart disease 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Colon & Rectal Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record